Search - tctmd.com

Displaying 1 - 20 of 167

Sort: Relevancy | Date

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

To Pretreat or Not to Pretreat? The DUBIUS Trial

Presenter: Roxana Mehran, Ferdinando Varbella, Giuseppe Tarantini

November 01, 2016

Presentation TCT 2016

Case Introduction: An Elderly Patient With NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Presentation TCT 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Contrast Reduction Strategies in the Patient With CKD

Presenter: Somjot S. Brar, Richard Solomon, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Pragmatic Simple Trials and Big Data: Implications for NIH Funding

Presenter: Deepak L. Bhatt, Roxana Mehran, Michael S. Lauer

October 31, 2016

Presentation TCT 2016

Pragmatic Simple Trials and Big Data: Advantages and Caveats

Presenter: Deepak L. Bhatt, Roxana Mehran, Robert A. Harrington

October 31, 2016

Presentation TCT 2016

Device Specifications and Clinical Program Update: Orbus-Neich Combo

Presenter: Alexandre Abizaid, Ashok Seth, Roxana Mehran

October 31, 2016

Presentation TCT 2016

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Presenter: John A. Bittl, Daniel I. Simon, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Levels of Evidence: Single-center vs Multicenter Trials

Presenter: Peter Juni, E. Magnus Ohman, Roxana Mehran

October 30, 2016

Presentation TCT 2016

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Presenter: Roxana Mehran, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus

October 30, 2016

Presentation TCT 2016

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Presenter: Roxana Mehran, Pascal Vranckx, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Stent Design and Comprehensive Data Review: Resolute Cobalt Chromium Durable Polymer-Based Zotarolimus-Eluting Stents

Presenter: Dean J. Kereiakes, Pieter C. Smits, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Scott Berry

October 30, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Stuart J. Pocock

October 30, 2016

Presentation TCT 2016

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Presenter: Roxana Mehran, Pascal Vranckx, Robert A. Harrington

October 30, 2016

Presentation SOLACI 2016

The Unmet Needs of DES

Presenter: Roxana Mehran

June 09, 2016

Advertisement

Case Conclusion: How Did We Treat Our Patient?

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

To Pretreat or Not to Pretreat? The DUBIUS Trial

Case Introduction: An Elderly Patient With NSTE-ACS

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Contrast Reduction Strategies in the Patient With CKD

Pragmatic Simple Trials and Big Data: Implications for NIH Funding

Pragmatic Simple Trials and Big Data: Advantages and Caveats

Device Specifications and Clinical Program Update: Orbus-Neich Combo

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Levels of Evidence: Single-center vs Multicenter Trials

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Stent Design and Comprehensive Data Review: Resolute Cobalt Chromium Durable Polymer-Based Zotarolimus-Eluting Stents

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

The Unmet Needs of DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content